Non-Opioid Pain Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Non-Opioid Pain Treatment Market is segmented By Drug Type (NSAIDs, Corticosteroids, Medical Cannabis Treatment, Menthol-Containing Treatment, Others), By Application (Orthopedic and Musculoskeletal Pain, Neuropathic Pain, Cancer Pain, Other Pain), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Non-Opioid Pain Treatment Market Overview

Non-Opioid Pain Treatment Market is expected to grow at a CAGR of 8% during the forecast period (2024-2031). Types of pain include chronic headaches, back pain, pain associated with surgery or treatments, sports injuries, and accidents. Every year, millions of prescriptions are written for pain medications, out of which many are powerful opioids that can cause side effects and lead to addiction. Non-opioid drugs include acetaminophen, commonly known as paracetamol. These drugs are not derived from opium and also include non-steroidal anti-inflammatory drugs (NSAIDs). Non-opioid drugs are majorly used for the treatment of mild to moderate pain and are sometimes used alongside stronger painkillers.

Non-Opioid Pain Treatment Market Scope

For More Insights Request Free Sample

Public visit to any emergency department of any medical center is generally because of pain. Patients suffering from cancer and arthritis suffer from chronic pain. In the case of cancer chemotherapy, radiation therapy and others lead to severe pain. According to the Centre for Disease Control and Prevention (CDC), 20.4% of U.S. adults had chronic pain, and 8% of U.S. adults had high-impact chronic pain in 2016. Pain management is one of the most commonly dealt-with issues by clinicians for any disease. Pharmacological therapy is the first line of therapy, followed by treatment via devices in severe pain management cases.

The market is currently gradually inclining towards the adoption of non-opioid medications to overcome the addiction toward opioids and certain well-established painkillers in the market. But there are many non-opioid treatments available for pain such as over-the-counter aspirin, ibuprofen, and acetaminophen, but some of them such as Celebrex, Cataflam, and Motrin, are prescription-only drugs. Several non-opioid drugs are currently in early and late-stage development. The federal authorities of multiple countries are working to shift to alternative approaches, and thus, fast-tracking those drugs for early market approval.

Non-Opioid Pain Treatment Market Dynamics

The market is driven by rising geriatric population, rise in incidences of chronic pain, increase in opioid misuse, easy and effective non-opioid medication availability, and a robust pipeline in the market.

The geriatric population is more susceptible to developing diseases because of low immunity levels. Geriatric population forms the largest user base of a preventive and predictive medication. According to World Health Organization (WHO), by 2020, the number of people aged 60 years and older will outnumber children younger than five years and between 2015 and 2050, the proportion of the world's population over 60 years will nearly double from 12% to 22%. Due to growth in the geriatric population, there is a rise in the cases of arthritis, cancer, and chronic pain that increase the need for non-opioid drugs.

Addiction to opioid drugs is further pushing the government and non-government organizations to look for alternative approaches. Opioid misuse is rising as an epidemic, according to the American Society of Addiction Medicine, in 2018, around 19,293 people died from a drug overdose.

Lack of awareness among common people leads to a preference for alternative therapies, and the market has an abundance of counterfeit products. Even non-opioid drugs do not show long-term efficiency as required. These are the common factors hampering market growth.

Non-Opioid Pain Treatment Market Segmentation Analysis

The global non-opioid pain treatment market can be segmented by drug type as NSAIDs, Corticosteroids, Medical Cannabis Treatment, Menthol-Containing Treatment and by application as Orthopedic and Musculoskeletal Pain, Neuropathic Pain, Cancer Pain, and Other Pain.

Non-opioid drugs are used for various disease treatments; Arthritis is one of the most common diseases that use non-opioid pain management medications. The use of medical cannabis has improved pain management for patients suffering from pains due to various reasons such as arthritis pain or neuropathic pain due to common diseases and conditions, including cancer, diabetes, and others. Pain caused by cancer can be treated. In April 2016, CDC set new guidelines for cancer-related pains that recommend non-opioid therapies, such as non-steroidal anti-inflammatory drugs (NSAIDS) like aspirin and ibuprofen. According to the CDC, about nine out of ten cancer patients suffering from pain find relief by using a combination of these non-opioid medications. 

Non-Opioid Pain Treatment Market Geographical Share

Geographically, the global non-opioid pain treatment market is divided into North America, Europe, South America, Asia-Pacific, and the Middle East and Africa.

North America is expected to have a major share of the non-opioid pain treatment market. The growth of the market is due to a rise in chronic pain as well as cancer and arthritis. Another reason is the increase in cases of opioid misuse. Geriatric population is also on the rise, as per U.S. Census Bureau report, in 2018 among 7.9 billion people all over the world, 720.1 million or 8.8% were aged 65 or older. In just 15 years, the elderly population is estimated to increase by more than 60%. Increasing geriatric population is increasing the prevalence of diseases such as rheumatoid arthritis and cancer.

Furthermore, according to the CDC, over 30 million patients are affected by osteoarthritis each year, in the US. CDC further states that the total economic burden of prescription opioids in the US was $78.5 billion in 2018 and an estimated 2.7 million people in the US suffered from substance use disorders related to prescription opioids pain relievers. According to the Food and Drug Administration (FDA), prescription drug abuse is most prevalent in the US. Similarly, Canada, according to the Public Health Agency of Canada, in 2017, about 4,000 Canadians died from an opioid-related overdose. Also, each day, around 17 Canadians are hospitalized due to opioids poisoning.

Non-Opioid Pain Treatment Companies and Competitive Landscape

• Some of the major key players in the market are Aphria Inc., Aurora, Bedrocan, Canopy Growth Corp., Cara Therapeutics, Centrexion Therapeutics, Cronos Group, GW Pharmaceuticals, Medical Marijuana Inc., Medropharm Gmbh, Panag Pharma Inc., Tilray, US Worldmeds LLC, and Vanway.
• In May 2019, Cronos Group opens a cannabinoid device R&D facility, based in Israel.
• In April 2019, Canopy Growth announced a plan to acquire U.S. multi-state cannabis operator, Acreage Holdings at such a time when cannabis production and sale becomes federally legal in the US.
• In April 2019, Canopy Growth expanded its European footprint by acquiring Spanish licensed cannabis producer Cafina.
• In March 2019, Centrexion Therapeutics Corporation announced successful results from the Phase 2 TRIUMPH clinical trial of CNTX-4975 (trans-capsaicin) injection for the treatment of moderate to severe knee pain associated with osteoarthritis in the journal Arthritis & Rheumatology.